Author’s response to reviews

Title: PD-L1 assessment in pediatric rhabdomyosarcoma: a pilot study.

Authors:

Giulia Bertolini (giulia.bertolini@istitutotumori.mi.it)
Luca Bergamaschi (luca.bergamaschi@istitutotumori.mi.it)
Andrea Ferrari (andrea.ferrari@istitutotumori.mi.it)
Salvatore Renne (salvatore.renne@istitutotumori.mi.it)
Paola Collini (paola.collini@istitutotumori.mi.it)
Cecilia Gardelli (cecg@libero.it)
Marta Barisella (marta.barisella@istitutotumori.mi.it)
Giovanni Centonze (giovanni.centonze@istitutotumori.mi.it)
Stefano Chiaravalli (stefano.chiaravalli@istitutotumori.mi.it)
Massimo Milione (massimo.milione@istitutotumori.mi.it)
Maura Massimino (maura.massimino@istitutotumori.mi.it)
Michela Casanova (michela.casanova@istitutotumori.mi.it)
Patrizia Gasparini (patrizia.gasparini@istitutotumori.mi.it)

Version: 1 Date: 18 Jan 2018

Author’s response to reviews:

Editor's comments:

I would like to invite the authors for a resubmission after performing additional immunostains with a second antibody against PD-L1.

Given the low number of cases and the tumoral negativity in all cases it would be necessary to exclude a technical issue due to low sensitivity to tumoral PD-L1 expression of the antibody used in the study.

We thank you for the much appreciated advice.
We did perform additional immunostaining with a second anti-PD-L1 antibody (clone 22C3, Dako) available for diagnostic use in our Pathology Department. Images, tables and manuscript have been appropriately modified.

We now hope that our work can be considered for publication in BMC cancer journal.